Jesus Mayor, MD
General Practice · Houston, TXNPI 1689727257
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $164, 5.0 times the $33 reported in 2019.
Across 40 payments — averaging $18.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$170
- Pfizer$134
- Paratek Pharmaceuticals, Inc.$120
- Amgen$64
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$63
- Exact Sciences$44
- plus $126 from 6 others
Across 20 payments — averaging $5200.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$50K
- Sanofi Pasteur Inc.$32K
- Modernatx, Inc.$18K
- Orasure Technologies Inc.$4K
What the payments were for
- Food & beverage$720100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 9 | $170 |
| Pfizer | 8 | $134 |
| Paratek Pharmaceuticals, Inc. | 7 | $120 |
| Amgen | 3 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $63 |
| Exact Sciences | 2 | $44 |
| Azurity Pharmaceuticals, Inc. | 2 | $40 |
| Phadia US Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Novartis | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
How this compares
$720 in reported general payments places this provider in the 75th percentile of 8,074 general practice providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 39 | $67,500 |
| EliquisApixaban | 46 | $47,513 |
| JardianceEmpagliflozin | 30 | $40,527 |
| FarxigaDapagliflozin Propanediol | 33 | $33,095 |
| LinzessLinaclotide | 37 | $26,044 |
| XareltoRivaroxaban | 22 | $24,797 |
| TradjentaLinagliptin | 17 | $24,281 |
| TrulicityDulaglutide | 19 | $23,095 |
| JanuviaSitagliptin Phosphate | 14 | $17,742 |
| XiidraLifitegrast | 16 | $13,803 |
| MyrbetriqMirabegron | 18 | $13,533 |
| Dexlansoprazole DrDexlansoprazole | 12 | $4,942 |
| Gabapentin | 201 | $3,340 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $3,262 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 112 | $2,511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $134 | $47,51346 claims |
| Lilly USA, LLCTrulicity | $17 | $23,09519 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $13,53318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,074 general practice providers in Texas.
Other general practice in Houston
- Kathleen Szelei-StevensHouston$253K
- Zsolt GaramiHouston$111K
- Scott ColemanHouston$87K
- Rispba McCray-GarrisonHouston$70K
- Piya GandhiHouston$36K
- Terri AlaniHouston$30K
- Demetris GreenHouston$26K
- Steven XueHouston$19K
- Carol DupuisHouston$16K
- Rosita HamidiHouston$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.